Cited 0 times in
Cited 0 times in
Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T01:17:23Z | - |
dc.date.available | 2023-06-02T01:17:23Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194793 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Z. Qing | - |
dc.contributor.googleauthor | H.R. Kim | - |
dc.contributor.googleauthor | R.A. Soo | - |
dc.contributor.googleauthor | C.H. Chiu | - |
dc.contributor.googleauthor | H. Hayashi | - |
dc.contributor.googleauthor | S-W. Kim | - |
dc.contributor.googleauthor | S. Teraoka | - |
dc.contributor.googleauthor | D-W. Kim | - |
dc.contributor.googleauthor | H. Zhan | - |
dc.contributor.googleauthor | H. Zhao | - |
dc.contributor.googleauthor | H. Li | - |
dc.contributor.googleauthor | T.S.K. Mok | - |
dc.contributor.googleauthor | Y-L. Wu | - |
dc.identifier.doi | 10.1016/j.annonc.2022.07.1119 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0923753422029702 | - |
dc.citation.volume | 33 | - |
dc.citation.number | Supplement 7 | - |
dc.citation.startPage | S1007 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Supplement 7) : S1007, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.